| ²é¿´: 544 | »Ø¸´: 2 | |||
adslyeÒø³æ (ÕýʽдÊÖ)
|
[ÇóÖú]
¡¾´ð°¸¡¿Ó¦Öú»ØÌû
|
|
This variation seeks approval for changes to Methotrexate Injection 25 mg/mL and 100 mg/mL,£¨ involving a minor amendment in the drug substance manufacturing process, employed by Fermion OY, concerning a change in the final isolated intermediate.£© ¾ä×Ó·ÖÁ½²¿·Ö£¬À¨ºÅÄÚµÄΪһ²¿·Ö£¬½²µÄÊǵ×ÎïºÏ³ÉÖеÄÒ»´¦Ð޸ġ£Ã»ÓÐÉÏÏÂÎÄ£¬¹Ê·Ò빩²Î¿¼£º 1¡¢This variation²»ºÃ·Ò룬×ÜÖ®¾ÍÊÇijÖָı䡣 2¡¢ changes ²»ºÃ·Ò룬×Ü֮ĿµÄÊÇ»ñµÃÕâ¸öchangeµÄÅú¸´¡£ 3¡¢ involvingÕâ¸ö²åÈëÓïÓ¦¸ÃÖ¸µÄÊÇ changesµÄÒ»²¿·Ö£¬ÒÔ¼°ºóÃæ½ÓµÄ¶¼ÊÇÔÚ½«»¯Ñ§ºÏ³É£¬ÓëÇ°ÃæµÄÄÚÈÝÃ÷ÏÔ²»Í¬ÁË¡£ 4¡¢ isolated intermediate ·ÖÀëÖмäÌ壬ҩ»¯×¨ÓÐÃû´Ê ½ö¹©²Î¿¼£º Õâ¸ö±ä»¯£¬ÎªÁËÄܹ»»ñ׼ʹÓüװ±µûßÊ×¢Éä¼Á25 mg/mLºÍ100 mg/mL£¬ÒÔ¼°°üÀ¨ Fermion OY½øÐеÄÒ©Îïµ×ÎïÉú²úÁ÷³ÌÖеÄÒ»´¦Î¢Ð¡Ð޸ģ¬Õâ¸öÐÞ¸ÄÊÇÕë¶Ô×îÖյķÖÀëÖмäÌå¡£ |
» ²ÂÄãϲ»¶
±±¾©ÁÖÒµ´óѧ˶µ¼ÕÐÉú¹ã¸æ
ÒѾÓÐ4È˻ظ´
²ÄÁϵ÷¼Á
ÒѾÓÐ7È˻ظ´
»¯Ñ§¹¤³Ì085602 305·ÖÇóµ÷¼Á
ÒѾÓÐ10È˻ظ´
289Çóµ÷¼Á
ÒѾÓÐ15È˻ظ´
291 Çóµ÷¼Á
ÒѾÓÐ7È˻ظ´
274Çóµ÷¼Á
ÒѾÓÐ14È˻ظ´
309Çóµ÷¼Á
ÒѾÓÐ5È˻ظ´
292Çóµ÷¼Á
ÒѾÓÐ8È˻ظ´
Çóµ÷¼Á
ÒѾÓÐ4È˻ظ´
Ò»Ö¾Ô¸ Î÷±±´óѧ ×Ü·Ö282 Ó¢ÓïÒ»62 Çóµ÷¼Á
ÒѾÓÐ3È˻ظ´
» ±¾Ö÷ÌâÏà¹Ø¼ÛÖµÌùÍÆ¼ö£¬¶ÔÄúͬÑùÓаïÖú:
´ó¼Ò°ïæ·ÒëÒ»¾ä»°
ÒѾÓÐ3È˻ظ´
·ÒëÒ»¾ä»° ÐÂÒ©Ñз¢ ÑéÖ¤·½°¸·½Ãæ
ÒѾÓÐ6È˻ظ´
ÇóÖú·ÒëÒ»¾ä»°
ÒѾÓÐ4È˻ظ´
·ÒëÒ»¾ä»°£¬ÀÏÊǸоõ·Òë²»³öÄǸöÒâ˼£¡
ÒѾÓÐ1È˻ظ´
ÂÛÎÄÕªÒª·Òë Ò»¾ä»° ·Ç³£¸Ðл
ÒѾÓÐ1È˻ظ´
ÔÚÒ©ÎﻯѧÖÐ PK profile Ôõô·Òë ÊÇʲôÒâ˼°¡
ÒѾÓÐ11È˻ظ´
°ïæ·ÒëÒ»¾ä»° »¯Ñ§·½ÃæµÄ ллŶ
ÒѾÓÐ1È˻ظ´
°ïæ·ÒëÒ»¾ä»°
ÒѾÓÐ1È˻ظ´
ÇóÖúÒ»¾ä»°µÄ·Ò룬 ÉúÎïÒ½Ò©·½ÃæµÄ
ÒѾÓÐ4È˻ظ´
Ò»¾ä»°ÖÐÒëÓ¢£¬ÉúÎïרҵ Õæ³Ï¸Ð¼¤ÁË
ÒѾÓÐ1È˻ظ´
Ò»¾ä»°·Ò룬¹ØÓÚ»¯Ñ§¼ü·½ÃæµÄ
ÒѾÓÐ3È˻ظ´
°ïæ·ÒëÒ»¾ä»°
ÒѾÓÐ2È˻ظ´
·ÒëÒ»¾ä»°£¬Ð»Ð»
ÒѾÓÐ2È˻ظ´
·ÒëÒ»¾ä»°£¨objectives£©
ÒѾÓÐ6È˻ظ´
ÇóÖú·ÒëÒ»¾ä»°
ÒѾÓÐ2È˻ظ´
Çó·ÒëÒ»¾ä»°£¡ ÔÚÏßµÈ
ÒѾÓÐ3È˻ظ´













»Ø¸´´ËÂ¥